Ketotifen Unit Dose Stulln (Ketotifen)

Ketotifen blocks H1 histamine receptors on conjunctival cells, preventing histamine‑induced itching and redness. It also stabilises mast cells, limiting the release of inflammatory mediators like prostaglandins and leukotrienes, which together diminish ocular allergic inflammation.

The dosing regimen for Ketotifen Unit Dose Stulln is determined by the prescribing clinician based on the severity of the allergic eye condition, patient age, and response to therapy. The prescriber will specify the number of drops and frequency of administration.

Safety data for ketotifen in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing to pregnant or nursing individuals. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Ketotifen combines H1‑receptor antagonism with mast‑cell stabilisation, offering both immediate symptom relief and longer‑term reduction of allergic inflammation. Compared with agents that act solely as H1 antagonists, ketotifen may provide more sustained control of ocular allergy symptoms, though individual response can vary.

Ketotifen Unit Dose Stulln should be stored at ambient temperature, preferably below 25 °C. Keep the unit‑dose containers in their original packaging, protect them from moisture and direct sunlight, and ensure the seal remains intact until use.

The product is applied topically to the eye. The patient should wash their hands, tilt the head back, and instil the prescribed number of drops into the conjunctival sac of the affected eye(s). If wearing contact lenses, remove them before administration and replace after the drops have been absorbed.

Serious but rare risks include severe allergic reactions such as angio‑edema of the eyelids, corneal ulceration, and significant vision changes. Patients should seek immediate medical attention if they experience sudden eye pain, worsening redness, or loss of vision after using the drops.

Individuals with a known hypersensitivity to ketotifen or any component of the formulation should avoid using this product. It is also contraindicated in eyes with active infection, severe inflammation, or when the patient is using incompatible ocular medications without professional guidance.